Our data showed that patients with HER2-positive breast cancer had significantly higher frequencies of Treg cells compared with healthy individuals (8.4 vs 6%; P=0.021), whereas the frequency was similar for both HER2-positive and HER2-negative patients (8.4 vs 9.2%; P=0.27; Figure 1B). This evidence concerns the gene ERBB2 and breast cancer.